Investor Presentaiton

Timeline Since Public Listing alvotech STADA launches AVTO2 in EU ESG reporting portal launched JAMP Pharma Partnership Expansion Listing on Iceland Main Market Listing on Nasdaq US and First North Iceland Patient study for AVT03 initiated Fuji submits AVT04 marketing application AVTO2 IC¹ deemed approvable by FDA AVTO4 filing accepted in Europe CRL received for AVTO2 in US (1st BLA) Jun2 2 32 Jul 22 Aug 22 Sep 22 Oct 22 Nov 22 Dec 22 Jan 23 Feb 23 Mar 23 Apr 23 May 23 Patient study for AVT06 initiated STADA launches AVTO2 in Switzerland New $136 m financing facilities AVT04 filing accepted in US 2022 ESG disclosures updated PK study for AVT03 initiated AVTO2 approved in Australia BoD expansion CRL received for AVTO2 in US 5 1. IC Interchangeability; CRL was received noting site inspection requirement $137 Private Share Placement Fuji and Alvotech expand partnership PK study for AVT05 initated AVTO2 Approved in Saudi Arabia Patient study for AVT05 initiated Advanz Partnership Expansion for EU Legend Portfolio Commercial Corporate © ALVOTECH. ALL RIGHTS RESERVED

View entire presentation